Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00947284 · ClinicalTrials.gov registry record · NA
Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity
A NA study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00947284 is a NA study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 3 participants.
The verdict
NCT00947284, a NA study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
In previous clinical studies of post-surgical pain the investigators found that nalbuphine (Nubain), a narcotic pain killer, relieves pain more effectively when combined with low-dose naloxone (Narcan), a drug that is used to treat narcotic overdose. This finding was particularly true in men. The purpose of this study is to find out if nalbuphine combined with naloxone is more effective in relieving experimentally produced pain than either drug alone. A second reason for this study is to find out if study medications work more effectively in women or in men. Subjects will come to the University of California at San Francisco (UCSF) Clinical Research Center (CRC) for 4 study visits. The first visit will be a 2-hour screening to assess the subject for study eligibility. During the other three visits, the investigators will use a thermal stimulating device to produce temporary, non-injurious skin sensitivity that subjects will feel as painful. Changes in pain will be measured following the intravenous (i.v.) administration of study drugs. Three drug combinations will be administered, a different one each visit: 1) nalbuphine 5 mg and naloxone 0.4 mg , 2) naloxone 0.4 mg and saline (an inactive solution), nalbuphine 5 mg and saline. These drug combinations will be administered in random order; all subjects will receive all three combinations.
Interventions
- DRUG nalbuphine plus naloxone
- DRUG nalbuphine plus saline
- DRUG naloxone plus saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00947284
The ClinicalTrials.gov registry entry for NCT00947284 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nalbuphine plus naloxone is the first listed.
NCT00947284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00947284 about?
NCT00947284 is a clinical study titled "Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity". In previous clinical studies of post-surgical pain the investigators found that nalbuphine (Nubain), a narcotic pain killer, relieves pain more effectively when combined with low-dose naloxone (Narcan), a drug that is used to treat narcotic overdose. This finding was particularly true in men. The pu...
What is the current status of trial NCT00947284?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2010-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00947284?
The interventions under investigation include: nalbuphine plus naloxone (DRUG), nalbuphine plus saline (DRUG), naloxone plus saline (DRUG).
Who is sponsoring clinical trial NCT00947284?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.